Altimmune based in Maryland was recently seeking collaboration with an academic institution for developing a vaccine against COVID-19. The company has presently collaborated with the University of Alabama in Birmingham for further developments.
“We need to collaborate with the academic institutions to move this program forward, and we were looking for somebody that has sort of broad experience in biology and immunology, sort of overall development of vaccines. An institution that also has had clinical development experience and that’s where UAB is well suited for that,”
“They have all three of these components and, as we move forward with the development of the vaccine, we would not only need animal work initially but eventually we’ll need to conduct clinical trials. And then we believe that UAB can be our partner throughout that process.”
– Vipin Garg, CEO at Altimmune
The company is working on a physical vaccine, also named AdCOVID which will be mainly administered as an intranasal spray. The collaboration between UAB and Altimmune marks a great step towards bringing academia and the corporate world closer. This will help fuel the other to collaborate and bring more potential solutions through the expertise of both segments.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here